Lv1
22 积分 2025-09-25 加入
Efficacy and Safety of Spleen Tyrosine Kinase and VEGFR-2 Dual-Target Kinase Inhibitor (OT202) in Dry Eye
22天前
已完结
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
1个月前
已完结
Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours
1个月前
已完结
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
3个月前
已完结
Precision Immunotherapy to Improve Sepsis Outcomes
5个月前
已完结
Precision Immunotherapy to Improve Sepsis Outcomes
5个月前
已完结
Precision Immunotherapy to Improve Sepsis Outcomes
5个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
5个月前
已完结
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis
7个月前
已完结
Efficacy and safety of Syk/VEGFR-2 Dual-target Kinase Inhibitor (OT202) in Dry Eye: A Randomized, Vehicle-controlled, Phase 2 Trial
8个月前
已完结
皖公网安备34019202002308
